摘要
目的探讨重组人血管内皮抑素(恩度)静脉泵入联合窗口期化疗在晚期鳞状细胞肺癌治疗中的疗效及安全性。方法回顾性分析安徽省立医院呼吸内科2016年1月-2017年6月收治的34例ⅢB-Ⅳ期肺鳞癌患者,采用恩度持续静脉泵入联合窗口期化疗。具体方案:恩度15mg/m^2每天持续24h静脉泵入,连续7d;在第4天窗口期接受含铂两药方案化疗,21天为1周期。治疗2-6个周期,每2个周期评价疗效,每周期记录不良反应。结果 34例患者均完成至少2个周期的治疗,获完全缓解0例,部分缓解13例,稳定15例,进展6例;2、4、6周期有效率(RR)分别为38.24%、45%、40%;疾病控制率(DCR)分别为79.4%、85%、80%。治疗过程中与恩度相关的主要副作用有心电图S-T改变1例,高血压2例,未有严重毒副反应。结论恩度静脉泵入联合窗口期化疗治疗晚期肺鳞癌,近期治疗4周期时有效率和疾病控制率有明显增高,不良反应无明显增加。
Objective To investigate the safety and efficacy of durative transfusion of recombinant human endostatin combined with window period-chemotherapy in advanced lung squamous cell carcinoma（ SCC）. Methods From January 2016 to July 2017,34 cases of ⅢB-Ⅳ SCC patients were treated with endostatin（ 15 mg/m2） durative transfusion combined with window period chemotherapy. Endostar was durative transfused every 24 hours for 7 days,and in the fourth day of window a routine chemotherapy in a twenty-one day cycle was given. All patients were treated with two to six cycles. Efficacy was evaluated every two cycles,and side effects were recorded at the end of every cycle. Results All the patients received at least two cycles of treatment. Of all the patients,there were 0 case of CR,13 cases of PR,15 cases of SD and 6 cases of PD. The response rates in 2,4 and 6 cycles were 38. 24%,45% and 40%,and the disease control rate were 79. 4%,85%,80% respectively. Side effects were found including S-T change on electrocardiogram in one case and hypertension in two cases. No severe side effect was observed.Conclusion Endostar durative transfusion combined with window period chemotherapy for SCC is effective and safety,and a large prospective randomized controlled clinical study is worth to carry out in future.
作者
胡代菊
胡晓文
汪萤
HU Dai-ju;HU Xiao-wen;WANG Ying(Department of Respiratory Medicine, the First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui 230001, China)
出处
《临床肺科杂志》
2018年第6期1030-1034,共5页
Journal of Clinical Pulmonary Medicine
